Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Emergent BioSolutionsSTU:ER4 +1.49%61 ROC (Joel Greenblatt) % is 19.20% as of Mar. 2026, which is 1% above its 10-year median of 19.03. GuruFocus rates STU:ER4 with a GF Score™ of 61/100 and a GF Value™ of €4.21 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 982 Drug Manufacturers companies, Emergent BioSolutions ranks worse than 51.22% on this metric.
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. Emergent BioSolutions's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 19.20%.
The historical rank and industry rank for Emergent BioSolutions's ROC (Joel Greenblatt) % or its related term are showing as below:
STU:ER4'
s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -74.75 Med: 19.03 Max: 54.59
Current: 10.64
During the past 13 years, Emergent BioSolutions's highest ROC (Joel Greenblatt) % was 54.59%. The lowest was -74.75%. And the median was 19.03%.
STU:ER4's ROC (Joel Greenblatt) % is ranked worse than 51.22% of 982
companies
in the Drug Manufacturers industry
Industry Median: 11.45
vs STU:ER4: 10.64
Emergent BioSolutions's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was 0.00% per year.
The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.
Emergent BioSolutions ROC (Joel Greenblatt) % Related Terms
Emergent BioSolutions ROC (Joel Greenblatt) % Historical Data
* Premium members only.
The historical data trend for Emergent BioSolutions's ROC (Joel Greenblatt) % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:ER4 vs EOLS, ELTP, AKBA: ROC (Joel Greenblatt) % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Emergent BioSolutions's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Emergent BioSolutions ROC (Joel Greenblatt) % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Emergent BioSolutions's ROC (Joel Greenblatt) % distribution charts can be found below:
* The bar in red indicates where Emergent BioSolutions's ROC (Joel Greenblatt) % falls into.
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:
EBIT stands for Earnings Before Interest and Taxes.
Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.
GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.
Note:
The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a ROC (Joel Greenblatt) % of 19.20% mean?
Emergent BioSolutions (STU:ER4) has a ROC (Joel Greenblatt) % of 19.20% as of Mar. 2026. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Emergent BioSolutions and its competitors. This is near median its historical median of 19.03. According to the industry distribution chart, Emergent BioSolutions ranks #503 out of 982 companies in the Drug Manufacturers industry, placing it in the top 51.2%.
Is Emergent BioSolutions' ROC (Joel Greenblatt) % too high?
Emergent BioSolutions' current ROC (Joel Greenblatt) % of 19.20% is near median its 10-year median of 19.03. The Drug Manufacturers industry median ROC (Joel Greenblatt) % is 11.45. Emergent BioSolutions' value of 19.20% is 67.7% above this industry median. Based on the distribution chart, Emergent BioSolutions ranks #503 out of 982 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Emergent BioSolutions has a GF Score™ of 61/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Emergent BioSolutions' ROC (Joel Greenblatt) % compare to EOLS and ELTP?
According to the Drug Manufacturers industry distribution chart, Emergent BioSolutions ranks #503 out of 982 companies for ROC (Joel Greenblatt) %. This places Emergent BioSolutions in the lower half of its industry. The industry median ROC (Joel Greenblatt) % is 11.45. Emergent BioSolutions' value of 19.20% is 67.7% above this benchmark. While the company's 10-year median is 19.03 vs. the industry median of 11.45, Emergent BioSolutions has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROC (Joel Greenblatt) % for a Drug Manufacturers company?
The median ROC (Joel Greenblatt) % among Drug Manufacturers companies is 11.45, based on 982 companies in the industry. Companies in the top quartile (top 25%) have a ROC (Joel Greenblatt) % significantly above this median, while those in the bottom quartile fall well below. However, ROC (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Emergent BioSolutions's current ROC (Joel Greenblatt) % of 19.20% is 67.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROC (Joel Greenblatt) % mean?
A high ROC (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Emergent BioSolutions and its competitors. For the Drug Manufacturers industry, the median ROC (Joel Greenblatt) % is 11.45 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Emergent BioSolutions's current ROC (Joel Greenblatt) % is 19.20%, which is near median its own 10-year median of 19.03. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Emergent BioSolutions stock overvalued right now?
Based on GuruFocus' analysis, Emergent BioSolutions (STU:ER4) is currently considered Significantly Overvalued. The stock's GF Value™ is €4.21, compared to a current price of €6.46 — trading 53.3% above its estimated fair value. The current ROC (Joel Greenblatt) % is 19.20%, which is near median its 10-year median of 19.03 and 67.7% above the Drug Manufacturers industry median of 11.45. Emergent BioSolutions' overall GF Score™ is 61/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROC (Joel Greenblatt) % calculated?
ROC (Joel Greenblatt) % is calculated from a company's financial statements. For Emergent BioSolutions (STU:ER4), the current ROC (Joel Greenblatt) % is 19.20% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Emergent BioSolutions (STU:ER4) Overvalued in 2026?
Based on GuruFocus' analysis, Emergent BioSolutions stock appears to be overvalued.
The current stock price of €6.46 is trading 53.3% above its estimated GF Value™ of €4.21.
GuruFocus considers Emergent BioSolutions to be Significantly Overvalued.
Key valuation signals for STU:ER4:
ROC (Joel Greenblatt) %: 19.20% (near median its 10-year median of 19.03)
GF Value™: €4.21 vs. price of €6.46 (53.3% above fair value)
Industry Position: 67.7% above the Drug Manufacturers median (#503 of 982)
No single metric tells the full story. See the STU:ER4 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Emergent BioSolutions Inc offers public health products to the government and healthcare providers. Company operates in three segments namely Commercial Product, MCM Products, and Services segment. The Commercial Product Segment consisting of Nasal Spray; the MCM Products Segment consisting of Anthrax-MCM products, Smallpox-MCM products and Other Products and the Services Segment consisting of Bioservices portfolio. Geographically, the company operates in United States, Canada, and Others. It derives maximum revenue from United states. The company's products include: NARCAN Nasal Spray, KLOXXADO Nasal Spray, ACAM2000, ANTHRASIL, BAT, BioThrax, CNJ-016, raxibacumab injection, Ebanga, and others.
61GF Score
Get the complete analysis for STU:ER4
ROC (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:ER4 has been successfully added to your 
